Willingness to Use Long-Acting Injectable Cabotegravir and Associated Factors Among Men Who Have Sex with Men in Guangxi, China
Archives of Sexual Behavior · 2024-07 · 53 (7) · 2795-2806
DOI: 10.1007/s10508-024-02886-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Sexual Behavior, online erschienen am 07.06.2024. Verfasst von Lu Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, School of Public Health, Guangxi Medical University, 22, Shuangyong Road, Nanning, 530021, China. Hauptthemen laut MEDLINE: Homosexuality, Male, HIV Infections, Pre-Exposure Prophylaxis, Pyridones. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Ministry of Science and Technology of China, Guangxi Key Laboratory of AIDS Prevention Control and Translation.
Abstract (Originalsprache)
Cabotegravir (CAB-LA), the first long-acting injectable pre-exposure prophylaxis (PrEP), has been approved for use in the USA and is not currently on the market in China. However, willingness to use CAB-LA and associated factors among men who have sex with men (MSM) have not yet been evaluated in China. A cross-sectional study was conducted in Guangxi, China, in 2022 recruiting 1,006 MSM. Their mean age was 30.2 years, 74.2% had college or above education, and 48.6% had a monthly income between 3,000 and 5,999 Chinese yuan (CNY). Most (73.4%) had previously heard of PrEP while few (8.3%) had ever used this type of preventative medication. Willingness to use CAB-LA was 79.8% and was positively associated with eight variables: younger age, being married to a woman, having a low monthly income, having six or more male partners in the past six months, having only regular male partners in the past month, having a high perceived risk of HIV infection, and history of using PrEP. Ten other variables were not significantly associated with willingness to use CAB-LA. Among 894 participants who were willing to use or did not definitely reject using CAB-LA, the main concerns about CAB-LA were its side effects (90.2%), efficacy (63.6%), and high cost (58.2%). Only 14.7% were willing to pay more than 1,200 CNY (~US$180) every two months to use CAB-LA. The preferred injection places were centers for disease control facilities, hospitals, and social organizations. Many (89.0%) said that they would recommend CAB-LA to their male sexual partners. We conclude that willingness to use CAB-LA was high among MSM in Guangxi. However, implementation of CAB-LA faces tough challenges due to its high cost and the low use of PrEP. Peer education may play a large role in the implementation of CAB-LA in China.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology and Biostatistics, School of Public Health, Guangxi Medical University, 22, Shuangyong Road, Nanning, 530021, China.
- State Key Laboratory of Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Collaborative Innovation Center for Diagnosis an…
- Guangxi Key Laboratory of Major Infectious Disease Prevention Control and Biosafety Emergency Response, Guangxi Center for Disease Control and Prevention, Nanning, China.
- Division of AIDS Control and Prevention, Nanning Center for Disease Control and Prevention, Nanning, China.
- Division of AIDS Control and Prevention, Guangxi Center for Disease Control and Prevention, Nanning, China.
- Department of Epidemiology and Biostatistics, School of Public Health, Guangxi Medical University, 22, Shuangyong Road, Nanning, 530021, China. gxxieyihong@163.com.
ORCID-Profile: Yihong Xie
Förderung
- National Natural Science Foundation of China
- Ministry of Science and Technology of China
- Guangxi Key Laboratory of AIDS Prevention Control and Translation
Zitieren
APA
Liu, L., Ruan, Y., Chen, S., Tang, H., Liu, J., Jiang, Y., Pei, H., Huang, T., Lan, G., & Xie, Y. (2024). Willingness to Use Long-Acting Injectable Cabotegravir and Associated Factors Among Men Who Have Sex with Men in Guangxi, China. Archives of Sexual Behavior, 53(7), 2795-2806. https://doi.org/10.1007/s10508-024-02886-6
Vancouver
Liu L, Ruan Y, Chen S, Tang H, Liu J, Jiang Y, et al. Willingness to Use Long-Acting Injectable Cabotegravir and Associated Factors Among Men Who Have Sex with Men in Guangxi, China. Archives of Sexual Behavior. 2024;53(7):2795-2806. doi:10.1007/s10508-024-02886-6
BibTeX
@article{Liu2024,
author = {Liu, Lu and Ruan, Yuhua and Chen, Shiwen and Tang, Hongyang and Liu, Junhui and Jiang, Yu and Pei, Hengyan and Huang, Tengda and Lan, Guanghua and Xie, Yihong},
title = {Willingness to Use Long-Acting Injectable Cabotegravir and Associated Factors Among Men Who Have Sex with Men in Guangxi, China},
journal = {Archives of Sexual Behavior},
year = {2024},
volume = {53},
number = {7},
pages = {2795--2806},
doi = {10.1007/s10508-024-02886-6}
}
EUVIMED